Revive Therapeutics Ltd (RVVTF)

[Fress]

Kyungdong Pharmaceutical acquires permission to export raw materials for COVID-19 treatment 'surge'

[Asia Times = Reporter Kim Ji-ho] The news of the export license of bucillamine', which is being developed overseas as a treatment for Corona 19, is on the rise by Kyungdong Pharmaceutical.

According to industry sources, Kyungdong Pharmaceutical received a permit for export of raw materials from the Ministry of Food and Drug Safety on the 26th.

bucillamine is a treatment for rheumatoid arthritis, recently approved by the US Food and Drug Administration (FDA) for a phase 3 clinical trial by Canadian pharmaceutical company Revive Therapeutics to develop it as a treatment for COVID-19.

Like remdesivir, bucillamine is expected to re-create a drug for the treatment of Corona 19.

Quote:
Kyungdong Pharm Co stock is rising in S. Korea. The company received approval for exporting bucillamine on 11/26. The article mentions phase 3 trial by Revive. Click Google Translate and you should be able to read the article.

https://asiatime.co.kr/news/newsview.php?ncode=1065573304574349


$RVVTF